Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.42 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.35 |
| ▸ | PTP4A2 | Q12974 | 1/20 | 0.35 |
| ▸ | PTP4A1 | Q93096 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL177943 | 0.87 | CYP3A4 (0.48) | MAPTTSHRCACNA1BAPBA1CYP3A4 | |
| SCHEMBL7512684 | 0.85 | CYP3A4 (0.46) | MAPTTSHRCACNA1BAPBA1CYP3A4 | |
| SCHEMBL288622 | 0.85 | ALDH1A1 (0.39) | MAPTTSHRCACNA1BAPBA1CYP3A4 | |
| SCHEMBL2358955 | 0.83 | ALDH1A1 (0.60) | MAPTTSHRCACNA1BAPBA1CYP3A4 | |
| SCHEMBL21880057 | 0.82 | ALDH1A1 (0.41) | MAPTTSHRCACNA1BAPBA1CYP3A4 | |
| SCHEMBL15137029 | 0.80 | MAPT (0.39) | MAPTTSHRCACNA1BAPBA1CYP3A4 | |
| SCHEMBL7157164 | 0.79 | MAPT (0.38) | MAPTTSHRCACNA1BAPBA1CYP3A4 | |
| SCHEMBL7157167 | 0.79 | MAPT (0.38) | MAPTTSHRCACNA1BAPBA1CYP3A4 | |
| SCHEMBL28843514 | 0.78 | ALDH1A1 (0.48) | MAPTTSHRCACNA1BAPBA1CYP3A4 | |
| SCHEMBL4678968 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2021354-A2 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | Brystol-Myers Squibb Company (US) | 2009-02-11 | — | — | EP | claimed |
| US-20080045461-A1 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | claimed |
| EP-1883652-A2 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2008-02-06 | — | — | EP | claimed |
| WO-2007140284-A2 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-06 | — | — | WO | claimed |
| US-20070021346-A1 | N-terminally modified GLP-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-25 | — | — | US | claimed |
| WO-2006127948-A2 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-30 | — | — | WO | claimed |
| WO-1993014100-A1 | AMPHOTERICIN B DERIVATIVES, THEIR PREPARATION AND USE | SMITHKLINE BEECHAM PLC (GB) | 1993-07-22 | — | — | WO | claimed |
| US-20080003288-A1 | Responsive microgel and methods related thereto | SUPRATEK PHARMA INC. (CA) | 2008-01-03 | — | — | US | disclosed |
| US-7204997-B2 | Responsive microgel and methods related thereto | SUPRATEK PHARMA INC. (CA) | 2007-04-17 | — | — | US | disclosed |
| EP-1478403-A1 | RESPONSIVE MICROGEL AND METHODS RELATED THERETO | SUPRATEK PHARMA, INC. (CA) | 2004-11-24 | — | — | EP | disclosed |
| US-20030152623-A1 | Responsive microgel and methods related thereto | SUPRATEK PHARMA INC. (CA) | 2003-08-14 | — | — | US | disclosed |
| WO-2003063909-A1 | RESPONSIVE MICROGEL AND METHODS RELATED THERETO | SUPRATEK PHARMA INC. (US) | 2003-08-07 | — | — | WO | disclosed |
| US-6491903-B1 | NARROW MOLECULAR WEIGHT DISTRIBUTION SHELL-CORE POLYMERS HAVING HYDROPHILIC, CROSSLINKED PERMEABLE SHELLS AND HYDROPHOBIC CORES, USED FOR REDUCING BLOOD CHOLESTEROL AND BILE ACID UPTAKE IN INTERSTINES; DRUG DELIVERY | WASHINGTON UNIVERSITY | 2002-12-10 | — | — | US | disclosed |
| US-6383500-B1 | Particles comprising amphiphilic copolymers, having a crosslinked shell domain and an interior core domain, useful for pharmaceutical and other applications | WASHINGTON UNIVERSITY | 2002-05-07 | — | — | US | disclosed |
| EP-1112268-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AND HERBICIDES CONTAINING THEM | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2001-07-04 | — | — | EP | disclosed |
| WO-2000015633-A1 | CONDENSED HETEROCYLIC COMPOUNDS AND HERBICIDES CONTAINING THEM | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-03-23 | — | — | WO | disclosed |
| EP-0910351-A1 | PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS | G.D. Searle & Co. (US) | 1999-04-28 | — | — | EP | disclosed |
| EP-0907666-A1 | PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS | G.D. Searle & Co. (US) | 1999-04-14 | — | — | EP | disclosed |
| WO-1997049736-A2 | PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS | G.D. SEARLE AND CO. (US) | 1997-12-31 | — | — | WO | disclosed |
| WO-1997049387-A1 | PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS | G.D. SEARLE AND CO. (US) | 1997-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021346-A1 | N-terminally modified GLP-1 receptor modulators | GLP1R, GIPR, IAPP | MAPT 4680/4885TSHR 70/4885CACNA1B 2608/4885 |
| US-20080045461-A1 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, IAPP | MAPT 4720/4885TSHR 69/4885CACNA1B 2649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.